Acoramidis

About AstraZeneca

AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.

About BridgeBio Pharma

BridgeBio Pharma is a clinical-stage biotech with a mission to translate genetic insights into life-changing medicines for rare diseases and cancers. The company has achieved significant milestones, including three FDA approvals, a robust late-stage pipeline with six Phase 3 trials conducted, and a market valuation reflecting strong investor confidence. Its core strategy leverages a decentralized hub-and-spoke operational model to pursue multiple high-precision programs simultaneously, targeting conditions with clear genetic etiology and significant unmet need.

About BridgeBio Pharma

BridgeBio Pharma is a clinical-stage biotech with a mission to translate genetic insights into life-changing medicines for rare diseases and cancers. The company has achieved significant milestones, including three FDA approvals, a robust late-stage pipeline with six Phase 3 trials conducted, and a market valuation reflecting strong investor confidence. Its core strategy leverages a decentralized hub-and-spoke operational model to pursue multiple high-precision programs simultaneously, targeting conditions with clear genetic etiology and significant unmet need.

Therapeutic Areas